RegulatoryOfficial
Slovak regulator updates QRD Annex V after moving adverse reaction reporting form on its website
🇸🇰 ŠÚKL · Thu 19 Nov 2026
ŠÚKL has issued Version 36 of QRD Annex V to reflect the new website location of its suspected adverse drug reaction reporting form, with no regulatory action required.
The Slovak State Institute for Drug Control (ŠÚKL) has told marketing authorisation holders that QRD Annex V (EMA/67830/2013, Version 36) has been updated. The change follows the relocation of the form for reporting suspected adverse drug reactions on the ŠÚKL website. The notice was published on 19 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (ŠÚKL). AI-assisted; check the source before acting.
More Regulatory
All →
FDA extends review of Belite Bio's tinlarebant for Stargardt disease to May 2027
Belite Bio, Inc (BLTE) · Fri 20 Nov 2026
FDA publishes new and revised draft product-specific guidances on bioequivalence for generics
🇺🇸 FDA · Fri 20 Nov 2026
Dutch inspectorate posts Biotronik field safety notice on ICD and CRT-D lithium plating
🇳🇱 IGJ · Thu 19 Nov 2026
Allarity secures US patent on twice-daily stenoparib dosing, with protection expected into 2045
🇺🇸 Allarity Therapeutics, Inc. (ALLR) · Thu 19 Nov 2026
China approves HUTCHMED's Syk inhibitor SYVIK for chronic ITP and warm autoimmune haemolytic anaemia
HUTCHMED (China) Ltd (HCM) · Thu 19 Nov 2026
Scancell's melanoma DNA vaccine iSCIB1+ gets FDA RMAT designation ahead of Phase 3
Scancell Holdings plc · Thu 19 Nov 2026